ArticleMMWR. Morbidity and mortality weekly report2024
Treatment for Opioid Use Disorder: Population Estimates - United States, 2022.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evaluating comparative effect of non-pharmacological interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study.Pain medicine (Malden, Mass.) · 2026Pooled it
- The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review.Addiction biology · 2025Pooled it
- A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial.Addiction (Abingdon, England) · 2026Trial
- Beneficial effects of the rapid vs. standard procedure for injection naltrexone initiation operate through increased adjunctive medication use.Drug and alcohol dependence · 2026Trial
- Study Protocol for a Pain Self-Management Intervention to Reduce Pain and Improve MOUD Engagement in Primary Care: A Randomized Trial.Substance use & addiction journal · 2026Trial
- Cost-Effectiveness of the START Hospital Addiction Consultation Service for Opioid Use Disorder Treatment.JAMA network open · 2026Trial
- Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care: A Cluster Randomized Clinical Trial.JAMA network open · 2026Trial
- Implementation of mobile medical units for naloxone distribution and MOUD linkage in Ohio's HEALing Communities Study: a community case study.Frontiers in public health · 2026Trial
- Thresholds for adjunctive medication usage and probability of initiating injectable naltrexone.Addiction (Abingdon, England) · 2026Trial
- Implementation of a Mobile Digital Tool Supporting Medication for Opioid Use Disorder Treatment Improves Retention: Stepped-Wedge Cluster Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- A Long-acting Naltrexone Implant (iSTEP-N) for Opioid Use Disorder: First-in-Human Phase I Trial.Journal of addiction medicineTrial
- Examining the effects of pill counts on treatment retention in buprenorphine maintenance therapy.Drug and alcohol dependence reports · 2026Article
- How do services offered within opioid treatment programs vary based on state methadone policies?Journal of substance use and addiction treatment · 2026Article
- Patient Travel Experiences for Methadone Dosing Visits.JAMA network open · 2026Article
- Postoperative Opioid Use Prediction Calculator Performance in Patients Undergoing Gynecologic Surgery.JAMA network open · 2026Article
- Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Behavioural pharmacology · 2026Article
- Erectile dysfunction and subsequent substance abuse: a retrospective cohort study of US non-academic hospitals.Sexual medicine · 2026Article
- Genetic variation in BDNF is associated with opioid use disorder severity.Human genetics · 2026Article
- Variation in knowledge and attitudes among overdose prevention collaborations: Insights from fatality review teams.Drug and alcohol dependence · 2026Article
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2022, 81,806 opioid-involved overdose deaths were reported in the United States, more than in any previous year. Medications for opioid use disorder (OUD), particularly buprenorphine and methadone, substantially reduce overdose-related and overall mortality. However, only a small proportion of persons with OUD receive these medications. Data from the 2022 National Survey on Drug Use and Health were applied to a cascade of care framework to estimate and characterize U.S. adult populations who need OUD treatment, receive any OUD treatment, and receive medications for OUD. In 2022, 3.7% of U.S. adults aged ≥18 years needed OUD treatment. Among these, only 25.1% received medications for OUD. Most adults who needed OUD treatment either did not perceive that they needed it (42.7%) or received OUD treatment without medications for OUD (30.0%). Compared with non-Hispanic Black or African American and Hispanic or Latino adults, higher percentages of non-Hispanic White adults received any OUD treatment. Higher percentages of men and adults aged 35-49 years received medications for OUD than did women and younger or older adults. Expanded communication about the effectiveness of medications for OUD is needed. Increased efforts to engage persons with OUD in treatment that includes medications are essential. Clinicians and other treatment providers should offer or arrange evidence-based treatment, including medications, for patients with OUD. Pharmacists and payors can work to make these medications available without delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.